Program

Venue: Amstelzaal, VUmc, Amsterdam

Day 1 (3 December 2015) – Scientific program

8:30 – 9:30    Registration, Meet & Greet
9:30 – 9:40    Opening and Welcome, Arjen Brussaard

Session 1 – Opening Lecture
Session headed by Arjen Brussaard

9:40 – 10:30    Opening lecture - “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders”, Mathias Jucker (University of Tubingen and German Center for Neurodegenerative Diseases)

10:30 – 11:00 coffee break

Session 2 - Preclinical research and disease mechanisms
Session headed by Micha Wilhelmus

11:00 – 11:30    Invited lecture - Neurodegeneration and intracellular protein trafficking, Casper Hoogenraad (Utrecht University)
11.30 – 11.45    Selected lecture - The function of SERF in protein aggregation and Alzheimer disease, Esther Stroo (University of Groningen)
11:45 – 12:00    Selected lecture - Towards the understanding of the disease mechanism of vanishing white matter, Truus Abbink (VUmc)

Session 3 - Pecha Kucha
Session headed by Jeroen Hoozemans and Micha Wilhelmus

12:00 – 12:45 Short presentations of selected posters (7 min per presentation)
1) The molecular component of the neurodegenerative disorder spinocerebellar ataxia 19/22, Claudio Tiecher (University of Groningen)
2) Early-life stress modulates microglia function and Alzheimer’s Disease neuropathology in APPswe/PS1dE9 mice, Lianne Hooijmakers (University of Amsterdam)
3) The effect of acute BACE1 inhibition on early cognitive deficits in a mouse model of Aβ toxicity, Maarten Loos (Sylics, Amsterdam)
4) A new in vitro model for C9orf72 ALS/FTD, F.W. Riemslagh (Erasmus MC)
5) Improved CSF-based discrimination between Alzheimer patients and controls after correction for ventricular volumes, Linda J.C. van Waalwijk van Doorn (Radboud University Medical Center)
6) Gene-based analysis detects novel loci associated with frontotemporal dementia and its clinical subtypes, Aniket Mishra (VUmc)
12:45 – 14:30 Lunch and poster market

**Session 4 - New biomarkers and therapy**

Session headed by Jeroen Hoozemans

14:30 – 15:15 *Invited lecture* - The UPR as therapeutic target for neurodegeneration, *Giovanna Mallucci (University of Cambridge)*

15:15 – 15:30 *Selected lecture* - Cell-to-Cell Transmission of the Unfolded Protein Response and tau pathology, *Wiep Scheper (VU University Medical Center)*

15:30 – 15:45 *Selected lecture* - Role of TGF-βETA pathway in hereditary Cerebral Amyloid Angiopathy, *Laure Grand Moursel (Leiden University Medical Center)*

15:45 – 16:00 *Selected lecture* - Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to AD, *A.E. Leeuwis (VUmc)*

16:00 – 16:30 Refreshment break

**Session 5 - Towards Industry-Academia collaboration**

Session headed by Bonno Bouma, Emeritus Professor, UMC Utrecht

16:30 – 16:50 Models for drug discovery, *Armand Tepper (Crossbeta Biosciences)*

16:50 – 17:10 Target discovery in the synapse, *Guus Smit (VU university)*

17:10 – 17:45 CNS drug development, *Chris Parsons (Merz Pharmaceuticals)*

17:45 – 20:00 Reception sponsored by Crossbeta Biosciences
Day 2 (4 December 2015) – Scientific & Industry Alliance Program

8:45 Welcome and introduction, Arjen Brussaard & Wiesje van der Flier

Session 6 - Scientific program (Memorabel projects)

Session headed by Wiesje van der Flier

9:00 – 9:15 Wiesje van der Flier (VUmc) – ABIDE: Alzheimer’s Biomarkers in Daily Practice

9:15 – 9:30 Femke Bouwman (VUmc) – PAGE-AD: Pathological substrate of clinical variability in AD

9:30 – 9:45 Marcel Verbeek (Radboud UMC) – CAVIA: Cerebral Amyloid Angiopathy: Vascular Imaging and fluid markers of Amyloid deposition

9:45 – 10:00 Charlotte Teunissen (VUmc) – PRODIA: Development of biomarkers enabling early and accurate differential diagnosis of dementia

10:00 – 10:15 Kerensa Broersen (UTwente) – Exploring the potential of multi-target treatment for Alzheimer’s disease: towards an integrated and transdisciplinary approach

10:15 – 10:30 Pilar Martinez (MUMC) – Sphingolipids: a novel target in the treatment of Alzheimer Disease?

10:30 – 11:00 coffee break

Session 7 - Towards interventions

Session headed by Arjen Brussaard

11:00 – 11:30 Disease interventions, Stephan Schilling (Probiodrug)

“Developing anti pGlu-Ab therapies - a differentiated Ab approach to treat Alzheimer’s Disease”.

11:30 – 12:00 Disease interventions, Peter Lansbury (Lysosomal Therapeutics)

“a divide and conquer approach to Parkinson's disease”

12:00 – 12:30 Perspective on industry academia collaboration, John Allam (EIP Pharma)

“Translational Medicine Success: The Importance of Committed and Enduring Academic-Industry Collaboration”

12:30 – 13:00 Clinical trials, Philip Scheltens (Alzheimer Center Amsterdam)

“50 ways to improve your clinical trial in AD”

13:00 – 14:00 Lunch, partnering and refreshment break

Memorabel Projects = Scientific project supported by the Dutch Research Council (National Research Council N.W.O./ZONMW) on Neurodegeneration, involving industrial partnerships
Session 8 - *Industry meets academia and affiliates*

14:00-16:15  Round Table discussions (3 session of 40 minutes)

Round Table 1: Target Validation (Jeroen Hoozemans & Annemieke Rozemuller)
Round Table 2: Disease pathways (Pim van Nierop & Arjen Brussaard)
Round Table 3: iPS & Cellomics (Ruud Toonen & Ronald van Kesteren)
Round Table 4: PET and MRI imaging (Bart van Berckel & Hugo Vrenken/Mike Wattjes)
Round Table 5: Cognitive & functional measurements (Wiesje van der Flier & Roos Jutten)
Round Table 6: Clinical trial expertise & guidance (Philip Scheltens & Niels Prins)

16:15 - 17:00  Round up and panel discussion (with Probiodrug, Lysosomal Thx, EIPharma & NCA officials)

17:00 - 18:00 Drinks sponsored by Neuroscience Campus Amsterdam